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Abstract 
Background: Transfusion-transmitted malaria (TTM) is an accidental Plasmodium infection caused by whole blood 
or a blood component transfusion from a malaria infected donor to a recipient. Infected blood transfusions directly 
release malaria parasites in the recipient’s bloodstream triggering the development of high risk complications, and 
potentially leading to a fatal outcome especially in individuals with no previous exposure to malaria or in immuno-
compromised patients. A systematic review was conducted on TTM case reports in non-endemic areas to describe 
the epidemiological characteristics of blood donors and recipients.
Methods: Relevant articles were retrieved from Pubmed, EMBASE, Scopus, and LILACS. From each selected study 
the following data were extracted: study area, gender and age of blood donor and recipient, blood component 
associated with TTM, Plasmodium species, malaria diagnostic method employed, blood donor screening method, 
incubation period between the infected transfusion and the onset of clinical symptoms in the recipient, time elapsed 
between the clinical symptoms and the diagnosis of malaria, infection outcome, country of origin of the blood donor 
and time of the last potential malaria exposure.
Results: Plasmodium species were detected in 100 TTM case reports with a different frequency: 45% Plasmodium 
falciparum, 30% Plasmodium malariae, 16% Plasmodium vivax, 4% Plasmodium ovale, 2% Plasmodium knowlesi, 1% 
mixed infection P. falciparum/P. malariae. The majority of fatal outcomes (11/45) was caused by P. falciparum whilst 
the other fatalities occurred in individuals infected by P. malariae (2/30) and P. ovale (1/4). However, non P. falciparum 
fatalities were not attributed directly to malaria. The incubation time for all Plasmodium species TTM case reports was 
longer than what expected in natural infections. This difference was statistically significant for P. malariae (p = 0.006). 
A longer incubation time in the recipient together with a chronic infection at low parasite density of the donor makes 
P. malariae a subtle but not negligible risk for blood safety aside from P. falciparum.
Conclusions: TTM risk needs to be taken into account in order to enhance the safety of the blood supply chain from 
donors to recipients by means of appropriate diagnostic tools.
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Background
Malaria is an infectious disease caused by intracel-
lular protozoan parasites of the genus Plasmodium 
responsible for a potentially fatal acute febrile illness fol-
lowing invasion and multiplication in human red blood 
cells (RBCs) during their complex life cycle. Five species 
of Plasmodium are currently known to cause malaria 
in humans: the deadliest Plasmodium falciparum and 
Plasmodium vivax, Plasmodium malariae, Plasmo-
dium ovale, Plasmodium knowlesi. Malaria parasites 
are naturally transmitted by the infective bites of female 
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Anopheles mosquitoes during their blood meal. Malaria 
can manifest with severe symptoms leading to a fatal out-
come in non-immune individuals, often young children 
and pregnant women in endemic areas or naïve adults 
in non-endemic settings, and remains asymptomatic in 
adults who have acquired a premunition maintained by 
repeated antigen exposure.
Transfusion-transmitted malaria (TTM) is an acci-
dental Plasmodium infection caused by the transfusion 
of whole blood or a blood component from a malaria 
infected donor to a recipient, described for the first time 
by Woolsey in 1911 [1], that may cause severe clinical 
symptoms in the recipients, especially in those with no 
previous exposure to malaria or in immuno-compro-
mised patients due to other coexisting diseases. Several 
systematic reviews have addressed the knowledge gap 
still existing in the epidemiology of TTM in the United 
States [2], Canada [3] and the Americas [4].
Plasmodium falciparum, P. vivax and P. malariae are 
the species most frequently detected in TTM [5]. Various 
aspects of the parasite biology make this accidental route 
of infection feasible such as the persistence of infection: 
P. falciparum can persist for at least 1 year before being 
cleared, P. vivax for 3 years whereas P. malariae is known 
to remain as a chronic infection at low density for dec-
ades [6]. All Plasmodium species are able to survive in 
stored blood, even if frozen, and retain their viability for 
at least 1 week, possibly well over 10 days depending on 
the conditions of storage; in fact, microscopically detect-
able malaria parasites were present even after 28  days 
of storage at 4 °C although a decrease of infectivity after 
2  weeks was observed [6, 7]. An important difference 
between the natural infection and TTM is that the for-
mer undergoes an initial asymptomatic phase (pre-eryth-
rocytic) which allows the activation of innate immunity 
cells against malaria parasites. This early phase has 
advantages on both sides of the host parasite arms race: 
the innate immunity gives the naïve host time to develop 
a more specific protective immunity; meanwhile the 
parasites manipulate the host’s immune system in order 
to escape. Infected blood transfusions directly release 
malaria parasites in the recipient’s bloodstream trig-
gering the development of high risk complications and 
potentially leading to a fatal outcome [8]. Experimental 
evidence suggests that as few as 10 infected RBCs can 
be sufficient to transmit the infection; thus, even a small 
inoculum is potentially infectious. However, the mean 
incubation period for TTM is generally longer than the 
mean incubation period for the mosquito-transmitted 
malaria (MTM) for all Plasmodium species as reported 
by [9]: 16.0 (8–29) days for P. falciparum TTM compared 
to 13.1 (7–27) days in P. falciparum MTM; 57. 2 (6–106) 
days for P. malariae TTM compared to 34.8 (27–37) days 
for P. malariae MTM; 19.6 (8–30) days for P. vivax TTM 
compared to 13.4 (8–31) days for P. vivax MTM; 23 days 
for P. ovale TTM compared to 13.6 (11–16) days for P. 
ovale MTM [9]. Blood components such as RBCs, plate-
lets and plasma, are commonly transfused to treat vari-
ous conditions ranging from surgical procedures causing 
a temporary anaemia to a chronic one due to haemato-
logical disorders (haemoglobinopathies, glucose-6-phos-
phate-dehydrogenase (G6PD) deficiency, haemophilia). 
Blood banks require a preliminary screening of a poten-
tial blood donor to exclude the risk of current or previous 
infections which can be transmitted by a blood transfu-
sion, including malaria. Criteria for haemovigilance are 
defined by the World Health Organization (WHO) and 
are adapted to each country according to national guide-
lines. Some countries such as USA rely on a pre-donation 
questionnaire for the screening of potential infected 
donors whereas some others, including France, UK and 
Australia, use antibody testing on donors who are consid-
ered at risk on the basis of the preliminary questionnaire 
[3]. Appropriate diagnostic tools need to be employed 
in order to enhance the safety of the blood supply chain 
from donors to recipients tailored to the local TTM risk. 
The sensitivity and specificity of the screening strategy of 
blood donors remains the crucial issue in order to ensure 
the safety of blood transfusions particularly in the case of 
malaria: in fact, serological tests currently employed do 
not indicate the actual parasitaemia because antibody 
levels can remain elevated for many years after infection 
of P. falciparum and P. vivax [10]. Also, the initial clinical 
symptoms are generally aspecific making the diagnosis 
more difficult and resulting in a further delay. Delayed or 
missed diagnosis of P. falciparum in particular increases 
the risk of severe disease which may be fatal especially in 
non-immune individuals.
Furthermore new technologies are available to selec-
tively inactivate pathogens without damaging cells or 
plasma; a combination of riboflavin as a photosensitizer 
with a UV light illumination device (Mirasol System for 
Whole Blood; Terumo BCT, Lakewood, Colo.) proved 
to substantially reduce P. falciparum infectivity in whole 
blood samples without altering cell quality parameters 
[11]; this inactivation technology may well represent 
another layer of control to reduce the risk of TTM.
Lastly, infected recipients who do not develop any clin-
ical illness may become asymptomatic carriers and thus a 
reservoir of malaria parasites if competent vectors were 
to be present; this event has serious implications espe-
cially in non-endemic countries where the majority of the 
population has never been exposed to malaria parasites.
The primary objective of this systematic review was 
to describe the epidemiological characteristics of TTM 
in non-endemic countries based on data available in the 
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literature in order to evaluate the extent and dynamics of 
this particular risk of malaria transmission. The review 
specifically investigated: (i) which Plasmodium species 
are more often detected in TTM; (ii) if other Plasmo-
dium species besides P. falciparum are likely to cause a 
lethal outcome of TTM; (iii) whether the incubation 
time in TTM is longer than in the natural infection; (iv) 
which blood component is more likely to be infective 
for the recipient (whole blood, red blood cells, platelets 
or plasma); (v) which diagnostic methods were used in 
donor screening and recipient diagnosis (microscopy, 
serological or molecular tests).
Methods
Literature search
A systematic review of all articles on TTM in non-
endemic areas was carried out. Relevant articles were 
retrieved from Pubmed, EMBASE, Scopus, and LILACS 
databases using combinations of the following search 
terms: “malaria”, “blood transfusion”, “Plasmodium”, 
“transfusion”, adapted to each database without date or 
language restrictions until May 17th 2017. TTM cases 
in USA were retrieved from the annual Morbidity and 
Mortality Weekly Reports (MMWR) malaria surveillance 
reports. The following combination of MeSH and free 
string terms were used specifically in Pubmed:
((“Platelet Transfusion”[MeSH] OR “Transfusion 
Medicine”[MeSH] OR “Lymphocyte Transfusion”[MeSH] 
OR “Leukocyte Transfusion”[MeSH] OR “Eryth-
rocyte Transfusion”[MeSH] OR “Blood Compo-
nent Transfusion”[MeSH]) OR (Transfusion*)) AND 
((malaria*) OR (Plasmodi*) OR (malaria [MeSH])). Origi-
nal research papers were included and additional refer-
ences retrieved from narrative reviews; restriction to case 
reports was deemed necessary as the main scope of this 
systematic review was to investigate in fine details the rel-
evant characteristics of each reported case of TTM. Two 
independent investigators (FV, EM) screened titles and 
abstracts, selected articles for full text review, performed 
the final article selection; a third reviewer (AA) was con-
sulted in case of disagreement in order to reach a con-
sensus. Case reports were excluded if the Plasmodium 
species was described as “tertian” without further iden-
tification. Also, case reports occurred in malaria endemic 
countries were not considered unless the case report was 
ascertained to have happened in a non-endemic area of 
the country. Articles in Chinese, Russian, Arabic and 
Turkish languages without at least a summary in Eng-
lish were dropped. From each study the following data 
was extracted: study area, gender and age of blood donor 
and recipient, blood component transfused, Plasmodium 
species, malaria diagnostic method employed, blood 
donor screening method, incubation period (i.e. the time 
elapsed between the infected transfusion and the onset of 
clinical symptoms in the recipient), delayed diagnosis (i.e. 
time elapsed between the onset of clinical symptoms and 
the diagnosis of malaria), infection outcome, country of 
origin of the blood donor and time of the last potential 
malaria exposure. The protocol for this systematic review 
was published on PROSPERO database with the registra-
tion number CRD 42017062298.
Statistical analysis
The incubation time of each TTM case report was ana-
lysed through standard one sample two-tailed t-tests 
(level of significance α = 0.05) to evaluate the difference 
between incubation periods of TTM and MTM for each 
Plasmodium species. Reference mean values of MTM 
were drawn from the results shown by Dover and Schultz 
[9]. All statistical analyses were performed using R soft-
ware, version 3.3.3 [12].
Results
The number of selected papers at each step of the screen-
ing and criteria for exclusion/inclusion are reported in 
the flow diagram (Fig. 1); 100 case reports of TTM were 
retrieved for the purpose of this review and the main 
epidemiological data is provided by Table 1. Fifty-four of 
these case reports occurred in the American continent, 
38 in Europe, 3 in the Mediterranean area, 1 in India, 4 in 
South-East Asia. 
The first report of TTM went back to 1911 and the 
most recent occurred in 2015, both in USA. The age of 
TTM case reports ranged from premature children to 
an 85  years old individual. The partitioning of cases in 
children and adults (≥ 18 years) when age was available 
resulted in 2 children and 39 adults for P. falciparum, 14 
children and 12 adults for P. malariae, 8 children and 6 
adults for P. vivax, 1 child and 3 adults for P. ovale, and 
2 adults for P. knowlesi. Female versus male ratio was 1:1 
for recipients and 1:6 for donors.
i. Plasmodium species. The most common Plasmo-
dium species detected in TTM resulted to be P. falci-
parum (45%) and P. malariae (30%); P. vivax, P. ovale 
were less frequently observed: 16 and 4% respec-
tively; two TTM were caused by P. knowlesi (2%), and 
one by a mixed infection P. falciparum/P. malariae. 
Plasmodium praecox, an avian Plasmodium species, 
was described in a case report whose infection was 
acquired in Greece [13].
ii. Species involved in fatal outcomes. The majority of 
fatal outcomes (11/45) was indeed caused by P. fal-
ciparum whilst all the other fatalities occurred in 
individuals infected by P. malariae (2/30) and P. ovale 
(1/4).
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iii. Incubation period (IP). Table 2 shows the differences 
in the mean incubation times for each Plasmodium 
species between TTM and MTM. For all species, the 
mean incubation time in TTM was longer, but the 
most relevant difference was observed for P. malar-
iae (63.9 vs 34.6 days, p = 0.006).
iv. Blood component causing TTM. The vast majority 
of TTM cases were caused by whole blood and/or 
RBCs transfusion; however, two TTM cases due to 
platelets and one TTM case due to plasma only were 
reported.
v. Diagnostic method used for screening (if any) and 
diagnosis. They are also reported in detail in Table 1. 
Classical Light microscopy (LM) was the diagnostic 
method used in virtually all cases of TTM. Only in 
very few cases this was complemented by serology 
(IFAT: first time in 1974 for a case of P. malariae 
occurred in US, ex-Cyprus) and/or PCR (first time in 
1995 for a case of P. falciparum occurred in Canada, 
ex-Mali). Donor “screening” was in fact in the ear-
lier cases the diagnosis subsequently made on the 
donor, classically with microscopy. Serology (IFAT) 
was first reported on donors in 1968 (a case of P. fal-
ciparum occurred in UK, ex-Africa, and a case of the 
same species occurred in US, ex-Vietnam). When 
reported, serology (most often IFAT) appears to 
be by and large the most frequent method used for 
donor screening.
Discussion
Transfusion-transmitted malaria is an alternative acci-
dental Plasmodium infection which may cause morbid-
ity and mortality especially in non-endemic areas where 
individuals have no premunition to malaria. Given the 
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long-time span, over a century, of the case reports some 
countries which were endemic several decades ago are 
now malaria free such as the case of Greece and Italy. 
Therefore, it was not possible to infer any particular geo-
graphical pattern of TTM, whose occurrence may reflect 
people movements due to historical events as well as the 
proximity to a malaria endemic areas; an example is pro-
vided by the numerous army returnees from Vietnam to 
USA in the late 1960s who were not identified at the time 
as potential malaria infected blood donors, and caused an 
increase of TTM cases in the following years in USA [9]. 
Also, a limitation of this systematic review was due to the 
selection of exclusively case reports in order to describe 
the main characteristics of each episode; thus, prevalence 
studies were discarded as well as data on the occurrence 
of “transfusion outbreaks” such as the 54 cases of P. vivax 
TTM reported by the WHO to have taken place in Spain 
in 1971 due to a single blood bank in Barcelona [14]. Fur-
ther limitations are due to the intrinsic nature of a sys-
tematic review based on different reports hampering the 
possibility to ascertain retrospectively how reliable were 
the clinical history and the timing of the diagnosis for 
each TTM case. The majority of fatal outcomes (11/45) 
was indeed caused by P. falciparum whilst all the other 
fatalities occurred in individuals infected by P. malariae 
(2/30) and P. ovale (1/4). However, these other fatalities 
were not attributable to malaria: two deaths were due to 
pneumonia and one was due to the complications of a 
premature newborn. Furthermore, all fatalities caused by 
P. falciparum were observed in adults and elderly people, 
which may reflect other co-morbidities or a more severe 
prognosis of malaria in adults compared to children 
within non-immune populations [15].
There are important differences between malaria nat-
ural infection and TTM with respect to the incubation 
time and delayed diagnosis: a longer incubation period 
was observed for all Plasmodium species as reported by 
Dover and Schultz [9] despite the absence of the pre-
erythrocytic phase as the infected blood component 
directly transmits the erythrocytic stage of the parasite, 
namely the merozoite, to the recipient. This paradoxical 
phenomenon might be explained by the small inoculum 
of parasites from an asymptomatic donor which requires 
a longer period of time to develop the clinical symptoms 
[6]. The incubation period of TTM case reports was con-
firmed to be longer than the one described in natural 
infections as shown in Table 2: the difference reached sta-
tistical significance (p =  0.006) in P. malariae, which is 
arguably the species with the longest incubation time and 
lowest parasite density. No other statistically significant 
difference was observed possibly due to the limited num-
ber of case reports, thus any interpretation must be taken 
with caution. Moreover, particularly in some cases of P. 
falciparum, the IP was surprisingly and unusually long, 
and, although it might explained in theory by an exceed-
ingly small number of parasites inoculated, a reporting 
error cannot be excluded. Nevertheless, such potential 
error is expected to have occurred across all TTM cases, 
thus making the observation still useful to reinforce the 
need to extend the window of time for a malaria diagno-
sis in blood transfusion recipients beyond the expected 
IP. Moreover, according to the reported data none of the 
TTM cases occurred in individuals with previous history 
of malaria, thus ruling out the possibility of recrudes-
cence, circulating anti-malarial antibodies (as it would be 
the case in malaria endemic areas), or prophylaxis which 
might have delayed the onset of symptoms and diagno-
sis. Interestingly, the incubation time of the only mixed 
P. falciparum and P. malariae infection was of 15 days, a 
nearly typical incubation time for the dominant P. falci-
parum species compared to the milder P. malariae which 
employs 35 days on average to clinically develop.
Furthermore, the observation that almost half of the 
TTM cases reported in this systematic review are due to 
P. malariae (N = 30) and P. vivax (N = 16) reinforces the 
need to consider these other Plasmodium species as a not 
negligible cause of transfusion-transmitted malaria aside 
from P. falciparum.
Several layers of complexity underline the risk of TTM 
in non-endemic areas: on one hand, the limited propor-
tion of potentially infective donors imposes a cost-effec-
tive strategy of blood donors screening, on the other 
hand the accuracy of such screening needs to be opti-
mal for the serious outcomes of TTM in malaria naïve 
recipients.
In most non-endemic countries the first step in the 
blood supply chain is an epidemiological questionnaire to 
assess the potential donor’s risk to be infective which may 
Table 2 Mean values of transfusion-transmitted malaria 
(TTM) versus mosquito-transmitted malaria (MTM) incuba-
tion time in days
CI confidence interval
Significance threshold p value <0.05 (in italic)
a As reported by Dover and Schultz [9]
b Obtained through one sample two-tailed Student’s t test, using the MTM 
mean value for the null hypothesis
c A range of the mean incubation time for this species in humans was not 
available in literature, so a direct comparison of CIs was not possible
Species TTM (95% CI) MTM (95% CI)a p  valueb
P. falciparum 25.7 (7.4–43.9) 13.1 (7–27) 0.172
P. malariae 63.9 (43.5–84.4) 34.8 (27–37) 0.006
P. ovale 19.0 (11.7–26.3) 13.6 (8–31) 0.118
P. vivax 29.3 (12.3–46.2) 13.4 (11–16) 0.060
P. knowlesic 15.5 (9.1–21.9) 10.0 (/) 0.058
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result in a deferral for two groups of individuals: (i) those 
who were born and had lived for several years in malaria-
endemic areas and (ii) those who were born and are resi-
dent in non-endemic areas but had visited an endemic 
area. According to the European guidelines individuals 
are acceptable as blood donors when an immunologic 
or molecular test for malaria is negative after at least 
6 months since their last visit to an endemic area. When 
these donors have resided for more than 3 months in the 
endemic area, the deferral time may be longer. However 
long the deferral does not totally exclude infectious semi-
immune individuals: in fact cases of TTM have been 
linked to donations given more than 5 years after the last 
potential exposure of the donor to P. falciparum and sev-
eral decades in the case of P. malariae [3].
Conclusions
i. The Plasmodium species most commonly involved in 
TTM were, expectedly, P. falciparum and P. malar-
iae, but cases of P. vivax were not infrequent, either. 
This parasite is not known to remain so long in blood 
as the two other species, while it shares with P. ovale 
the phenomenon of hepatic hypnozoites (that, how-
ever, are not a possible source of transmission before 
they reach again the bloodstream).
ii. Species involved in fatal outcomes. All fatal out-
comes attributable to malaria were caused by P. fal-
ciparum and none by P. vivax, a parasite that has 
long been  considered benign, although its potential 
to cause severe malaria has been repeatedly demon-
strated in recent years [16].
iii. The incubation period was longer than the average IP 
for mosquito-transmitted malaria, which may be a fur-
ther reason for lack of suspicion and diagnostic delay.
iv. Almost all TTM cases were caused by whole blood 
and/or RBCs transfusion, as expected, but for two 
cases by platelets and one by plasma only.
v. Classical Light microscopy (LM) was used in all 
cases of TTM for diagnostic purposes. Only in very 
few cases this was complemented by serology and/or 
PCR in the more recent period. Serology (IFAT) was 
the most frequently used method for donor screen-
ing.
WHO regulations on blood donation needs to be rein-
forced as many of the TTM case reports observed even in 
the time span since blood safety guidelines were imple-
mented could have been prevented if those guidelines 
had been applied with stringency. Thus, different strate-
gies need to be combined in order to ensure the safety of 
blood transfusions i.e. blood donor screening by appro-
priate diagnostic tools, which should probably include 
molecular tests, and possibly parasite inactivation of the 
blood supply.
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